Clinical Trial Update: Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received Three Doses of the Same Vaccine [Phase 2]

View source ↗

Summary

Extension Phase 2 study evaluating antibody persistence, safety, tolerability, and immunogenicity of a booster dose of Novartis rMenB±OMV NZ vaccine in healthy …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• Novartis rMenB±OMV NZ Vaccine

Snippet

Sponsor: Novartis Vaccines | Conditions: Meningococcal Disease | Phase 2 | Status: COMPLETED | Results posted: 2014-03-11